24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
Corporate
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Kare Schultz
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
Corporate
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
21:53
Binance is back online after a record crypto theft. The questions are far from settled
20:53
From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits
20:25
"Security teams are struggling to handle this AI threat"
20:24
"To build a company in Israel for the last four years is not an easy mission"
More stories
Buzz
Most popular
Daily
Weekly
1
Israeli startup Coldi is deploying AI agents to take over the cold call
2
Perion to be acquired by India’s Affle for $420 million, marking a steep fall for a once-billion-dollar Israeli company
3
ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years
4
From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits
5
"A gorgeous situation": ServiceNow's CEO celebrates a shrinking workforce
More news
Kare Schultz
6 stories about Kare Schultz
Closure of another criminal case will help Teva's new CEO to focus on return to growth
22.08.23
|
Sophie Shulman
The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations
Schultz kept Teva away from the abyss, but couldn't find a runway to growth
22.11.22
|
Sophie Shulman
Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines
Teva in talks with Covid-19 vaccine manufacturers to co-produce shots
10.02.21
|
Reuters and CTech
"We are positive towards contributing by manufacturing some of those vaccines that either have been approved or are just about to be approved," said CEO
Teva beats analysts predictions with increased revenues from growth drivers
10.02.21
|
Sophie Shulman
The Israeli pharmaceutical company concluded the quarter with $4.5 billion in revenues, bringing it to a total of $16.6 billion for 2020
Generic Drugmaker Teva Says Profit Will Continue to Drop in 2018
08.02.18
|
Dror Reich
Israel’s Teva reports a $17-billion goodwill impairment citing the decline of the U.S. generic market
New CEO to Break Teva’s Copaxone Habit
11.09.17
|
Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility